New treatments for people with multidrug-resistant (MDR) HIV are necessary to avoid hospitalization, progression to AIDS, and death.1 Lenacapavir (Sunlenca, Gilead) was approved by the FDA on December 22, 2022, for the treatment of HIV-1 infection in heavily treatment-experienced adults with MDR HIV-1 infection failing their current antiretroviral (ARV) regimen due to resistance, intolerance, or safety considerations.2 Lenacapavir was approved